Health Economics›Colorectal cancer›Neoadjuvant therapy

Neoadjuvant therapy

Colorectal cancer · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ipilimumab and Nivolumab Variant #01 Partial	MSI-H	R 78 615	42d	—	~18.2 mo	~4	~R 314 461 PFS proxy · indirect	2

1 of 1 regimen shown